Abattis Comments on OTC Market's Request
The original release is unavailable here.
Abattis Bioceuticals Corp on 6ix
Story so far
Earlier from Abattis Bioceuticals
- Abattis Unveils “Comfort”, Its Proprietary New Chronic Pain and Inflammation Product to Start Shipping November 2018
- Abattis Strengthens Management Team and Provides Company Updates
- Abattis Prepares to Launch New Products Through Vergence Naturals
- Emerald Health Therapeutics Completes Acquisition of Licensed Dealer Northern Vine Canada
- Abattis Completes Sale of Northern Vine Interest
Later from Abattis Bioceuticals
- Abattis Bioceuticals Provides Phase 1 Update on Research and Development for Nanoemulsification and Liposomal Platforms of Cannabinoid-Rich Hemp Oil
- Abattis Bioceuticals Provides Update on Vaporizer Product Line
- Abattis Bioceuticals Celebrates Legalization
- Abattis Retains Canadian and American Compliance Agency and Provides Company Update
- Abattis Bioceuticals Acquires Proprietary Genetic Strain Bank
Follow Abattis Bioceuticals into a list and get an email when it puts out news.
Follow Abattis Bioceuticals